Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study ID
NCT06551896
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pemigatinib — DRUG
    Pemigatinib and immune checkpoint inhibitors

Study Details

This prospective phase Il study is aim to evaluate the efficacy and safety of FGFR inhibitor combined with immune checkpoint inhibitors in FGFR1/2/3 variant advanced solid tumors.

Key Dates

First listed
Aug 13, 2024
Start date
Aug 15, 2024
Status verified
Aug 2024
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pemigatinib combined with immune checkpoint inhibitor
    Pemigatinib 13.5mg，two weeks on and one week off, and with immune checkpoint inhibitor selected by investigator.

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: every 8 weeks during treatment ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsGastric cancer trialsLung cancer trialsBladder cancer trialsOncology trialsBreast oncology trialsWomen's health trialsGI oncology trialsLung oncology trialsLung disease trialsUrology trials

Related Studies